New immune cell therapy targets Hard-to-Treat blood cancer
NCT ID NCT07510100
First seen Apr 03, 2026 · Last updated May 06, 2026 · Updated 4 times
Summary
This early-phase study tests a new treatment called Equecabtagene Autoleucel for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The goal is to see if it is safe and can shrink tumors, but it is not expected to be a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Science Tokyo Hospital
Bunkyo-ku, Tokyo, 113-8519, Japan
Contact
-
Japanese Red Cross Medical Center
Shibuya-ku, Tokyo, 150-8935, Japan
Contact
-
Nihon University Itabashi Hospital
Itabashi-ku, Tokyo, 173-8610, Japan
Contact
Conditions
Explore the condition pages connected to this study.